Insulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms.

2.50
Hdl Handle:
http://hdl.handle.net/10147/248819
Title:
Insulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms.
Authors:
Corvin, Aiden P; Molinos, Ines; Little, Graham; Donohoe, Gary; Gill, Michael; Morris, Derek W; Tropea, Daniela
Affiliation:
Neuropsychiatric Genetics Research Group, Department of Psychiatry, Trinity College Dublin, St. James Hospital, Dublin 8, Ireland.
Citation:
Insulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms. 2012, 520 (1):51-6 Neurosci. Lett.
Journal:
Neuroscience letters
Issue Date:
27-Jun-2012
URI:
http://hdl.handle.net/10147/248819
DOI:
10.1016/j.neulet.2012.05.029
PubMed ID:
22609570
Abstract:
Insulin-like growth factor-1 (IGF1) and its active peptide (1-3)IGF1 modulate brain growth and plasticity and are candidate molecules for treatment of brain disorders. IGF1 N-terminal portion is naturally cleaved to generate the tri-peptide (1-3)IGF1 (glycine-praline-glutamate). IGF1 and (1-3)IGF have been proposed as treatment for neuropathologies, yet their effect on nerve cells has not been directly compared. In this study we examine the effects of IGF1 and (1-3)IGF1 in primary cortical cultures and measure the expression levels of markers for intracellular pathways and synaptic function. We find that both treatments activate the IGF1 receptor and enhance the expression of synaptic markers, however, they activate different intracellular pathways. Furthermore, (1-3)IGF1 administration increases the expression of endogenous IGF1, suggesting a direct interaction between the two molecules. The results show that the two molecules increase the expression of synaptic proteins through activating different cellular mechanisms.
Item Type:
Article
Language:
en
MeSH:
Animals; Animals, Newborn; Biological Markers; Cells, Cultured; Cerebral Cortex; Humans; Insulin-Like Growth Factor I; Mice; Mitogen-Activated Protein Kinases; Neurons; Peptide Fragments; Phosphatidylinositol 3-Kinases; Phosphorylation; Primary Cell Culture; Receptor, IGF Type 1; Recombinant Proteins; Signal Transduction; Synapses
ISSN:
1872-7972

Full metadata record

DC FieldValue Language
dc.contributor.authorCorvin, Aiden Pen_GB
dc.contributor.authorMolinos, Inesen_GB
dc.contributor.authorLittle, Grahamen_GB
dc.contributor.authorDonohoe, Garyen_GB
dc.contributor.authorGill, Michaelen_GB
dc.contributor.authorMorris, Derek Wen_GB
dc.contributor.authorTropea, Danielaen_GB
dc.date.accessioned2012-10-15T14:06:47Z-
dc.date.available2012-10-15T14:06:47Z-
dc.date.issued2012-06-27-
dc.identifier.citationInsulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms. 2012, 520 (1):51-6 Neurosci. Lett.en_GB
dc.identifier.issn1872-7972-
dc.identifier.pmid22609570-
dc.identifier.doi10.1016/j.neulet.2012.05.029-
dc.identifier.urihttp://hdl.handle.net/10147/248819-
dc.description.abstractInsulin-like growth factor-1 (IGF1) and its active peptide (1-3)IGF1 modulate brain growth and plasticity and are candidate molecules for treatment of brain disorders. IGF1 N-terminal portion is naturally cleaved to generate the tri-peptide (1-3)IGF1 (glycine-praline-glutamate). IGF1 and (1-3)IGF have been proposed as treatment for neuropathologies, yet their effect on nerve cells has not been directly compared. In this study we examine the effects of IGF1 and (1-3)IGF1 in primary cortical cultures and measure the expression levels of markers for intracellular pathways and synaptic function. We find that both treatments activate the IGF1 receptor and enhance the expression of synaptic markers, however, they activate different intracellular pathways. Furthermore, (1-3)IGF1 administration increases the expression of endogenous IGF1, suggesting a direct interaction between the two molecules. The results show that the two molecules increase the expression of synaptic proteins through activating different cellular mechanisms.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Neuroscience lettersen_GB
dc.subject.meshAnimals-
dc.subject.meshAnimals, Newborn-
dc.subject.meshBiological Markers-
dc.subject.meshCells, Cultured-
dc.subject.meshCerebral Cortex-
dc.subject.meshHumans-
dc.subject.meshInsulin-Like Growth Factor I-
dc.subject.meshMice-
dc.subject.meshMitogen-Activated Protein Kinases-
dc.subject.meshNeurons-
dc.subject.meshPeptide Fragments-
dc.subject.meshPhosphatidylinositol 3-Kinases-
dc.subject.meshPhosphorylation-
dc.subject.meshPrimary Cell Culture-
dc.subject.meshReceptor, IGF Type 1-
dc.subject.meshRecombinant Proteins-
dc.subject.meshSignal Transduction-
dc.subject.meshSynapses-
dc.titleInsulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms.en_GB
dc.typeArticleen
dc.contributor.departmentNeuropsychiatric Genetics Research Group, Department of Psychiatry, Trinity College Dublin, St. James Hospital, Dublin 8, Ireland.en_GB
dc.identifier.journalNeuroscience lettersen_GB
dc.description.provinceLeinsteren
All Items in Lenus,the Irish health repository are protected by copyright, with all rights reserved, unless otherwise indicated.